Tiziana announces initiation of phase 1b clinical trial in crohn's disease patients to evaluate oral capsules of foralumab, a fully human anti-cd3 monoclonal antibody

New york, march 25, 2022 (globe newswire) -- tiziana life sciences (nasdaq: tlsa) ("tiziana" or the "company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today announced initiation of a phase 1b clinical trial to evaluate orally administered enteric-coated capsules of foralumab in patients with mild-to-moderate crohn's disease (cd). this revised protocol, as previously outlined in the company's announcement on february 4, 2022, allows for the study of a broader patient population and a shorter dosing period. these protocol amendments or revisions are intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.
TLSA Ratings Summary
TLSA Quant Ranking